The DUSP6 Knockout HeLa Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the HeLa cell line, designed for the targeted disruption of the dual-specificity phosphatase DUSP6. This polyclonal knockout model provides a heterogeneous pool of cells harboring loss-of-function mutations in the DUSP6 gene, enabling the study of DUSP6-dependent signaling and cellular phenotypes without the need for clonal isolation. The product is suitable for transient and stable assays investigating MAPK/ERK pathway regulation, and serves as an essential tool for functional genomics and drug discovery research.
The HeLa cell line is an immortalized epithelial cell line from a cervical adenocarcinoma (Henrietta Lacks, HPV-18 positive). As one of the most characterized human cell models, HeLa cells offer robust growth, straightforward transfection, and well-defined signaling pathways, making them ideal for oncogenic signaling and tumor biology studies. Using HeLa as the parental background permits direct interrogation of DUSP6-mediated feedback regulation in a transformed context.
DUSP6 encodes a dual-specificity phosphatase that selectively dephosphorylates activated ERK1/2 (MAPK1/3) on both phosphotyrosine and phosphothreonine residues, functioning as a key negative feedback regulator of the RAS-RAF-MEK-ERK signaling cascade. DUSP6 expression is transcriptionally upregulated by ERK1/2-responsive ETS transcription factors following stimulation by growth factors such as EGF and FGF, downstream of EGFR and FGFR. By attenuating ERK1/2 activity, DUSP6 modulates downstream targets including the transcription factor c-FOS and the cell cycle regulator cyclin D1, thereby influencing proliferation and survival. Loss of DUSP6 disrupts this feedback loop, leading to sustained ERK phosphorylation and potential hyperactivation of proliferative signaling.
In the HeLa cell background, knockout of DUSP6 provides a physiologically relevant model to examine altered signaling dynamics and therapeutic vulnerabilities. HeLa cells exhibit constitutive activity of the MAPK/ERK pathway due to transformation; elimination of the DUSP6 brake may further potentiate ERK-dependent proliferation and could enhance sensitivity to MEK or ERK inhibitors. This model thus enables the dissection of feedback regulation in the context of persistent oncogenic signaling, and serves as a platform to evaluate the role of DUSP6 in drug resistance mechanisms frequently observed in MAPK-driven cancers, including melanoma, non-small cell lung cancer, and pancreatic cancer.
Typical experimental applications include western blot analysis of phospho-ERK1/2 to confirm pathway dysregulation, cell proliferation and colony formation assays to assess growth phenotypes, and RT-qPCR to measure DUSP6 and downstream gene expression. This polyclonal knockout population is also valuable for high-throughput screening of small-molecule modulators targeting the MAPK/ERK axis, as well as for combinatorial studies with standard-of-care inhibitors to probe synthetic lethal interactions. Additionally, flow cytometry-based cell cycle analysis can reveal DUSP6-dependent effects on cell cycle progression. For more detailed technical support and ordering information, please contact Ascent Research.
